Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a fluid from amniotic cells ease ankle arthritis pain?

NCT ID NCT05092646

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study tests whether a single injection of Axolotl Ambient, a fluid rich in growth factors derived from human amniotic cells, can reduce pain and improve function in people with ankle osteoarthritis. Participants will be randomly assigned to receive either the investigational injection or a saline placebo, and neither they nor the researchers will know which they received. The trial focuses on measuring changes in pain and function scores over time, as well as safety.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Axolotl Ambient (CA20), a fluid derived from human amnion cells, injected into the ankle joint
What this could lead to
If it works, this could offer a new, non-surgical way to reduce ankle osteoarthritis pain and improve mobility.
What could go wrong
This is a small early-stage pilot study, so results may not hold up in larger trials. The injection could cause side effects or fail to outperform a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

12 people

The number who actually took part.

Started

Dec 2021

Finished

Nov 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Signed written informed consent 2. Willing to be randomized to either the investigational or control group 3. Male or female at least 18 years of age and less than 80 4. Clinical diagnosis of symptomatic tibiotalar (ankle) OA (primary idiopathic OA or post-traumatic OA), modified K-L grade 1-3a 5. One ankle is the most symptomatic lower extremity joint and the only lower extremity joint currently planned for treatment 6. Willing and able to comply with all study requirements including all postoperative clinical and radiographic evaluations 7. For women of childbearing potential (not post-menopausal for 12 months or surgically sterile), a urine pregnancy test with a negative result must be obtained at screening and on the day of procedure, prior to injection 8. Male and female trial participants must commit to adequate birth control (e.g., surgically sterilized, oral contraceptive, two methods of barrier birth control, or abstinence) through the final follow-up 9. Chronic ankle pain for ≥ 6 months 10. SAOS Pain score ≥ 30 and ≤ 80 and AOS Function score ≥ 30 and ≤ 80 11. Willing to discontinue all prescription and over-the-counter pain medications being used for ankle OA symptoms for the duration of the study, except for acetaminophen, which is not allowed for the 3 days preceding each scheduled follow-up visit and the day of the follow-up visit. Exclusion Criteria: 1. Previously received intra-articular injections in the index joint of Axolotl Ambient, bone marrow aspirate concentrate (BMAC), platelet-rich plasma (PRP), or other biologic-based products within the last 12 months. 2. Modified K-L Grade 3b or 4 osteoarthritis of the index joint 3. Diagnosis of ipsilateral peri-articular arthritis (e.g. subtalar joint) that the investigator determines may significantly confound the study results 4. Received intra-articular hyaluronic acid injection in the index joint within the last 6 months 5. Received intra-articular steroid injection in the index joint within the last 3 months 6. Prior major surgical repair or reconstruction of the ankle that the investigator determines may significantly confound the study results 7. Baseline pain catastrophizing score ≥ 23 8. Any surgery of the index ankle within the last 12 months 9. Planned arthroscopy or other procedure on the ankle during the study 10. Bilateral ankle OA requiring treatment of both ankles 11. Pregnancy, breastfeeding, or woman of child-bearing potential not using adequate contraception 12. Bone deficit 13. Charcot foot disease 14. Radiographic evidence of open epiphyses 15. Systemic inflammatory condition 16. Substantial vascular insufficiency 17. Current treatment with anticoagulants 18. Deformity in coronal, axial or sagittal plane greater the 30° 19. Patients weighing less than 47 kg. 20. BMI greater than 45 kg/m2 21. Documented medical history of, or radiographic evidence of, a bone disease (e.g. severe osteoporosis or avascular necrosis) or other condition (e.g., osteolysis) 22. Comorbidity that would limit the ability to administer any functional measurements 23. Has at the time of injection, a systemic or local infection at the site of injection 24. Medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the study or potentially decrease survival or interfere with ambulation or rehabilitation (e.g., history of transient ischemic attack, stroke or liver disease) 25. Known hypersensitivity to penicillin 26. Known allergy to phenol red 27. Currently receiving treatment with a drug known to interfere with bone or cartilage metabolism \[e.g., systemic steroid therapy (topical steroid therapy is permissible), methotrexate\] 28. Medical condition requiring radiation, chemotherapy or immunosuppression 29. Have an active history of malignancy (except for basal cell carcinoma of the skin) 30. Has a history of autoimmune disease known to affect bone or cartilage. Examples include spondyloarthropathies (e.g., ankylosing spondylitis, Crohn's disease, and ulcerative colitis), Juvenile Arthritis, rheumatoid arthritis, Grave's disease, and Hashimoto's thyroiditis 31. Has obvious or documented alcohol or illicit drug addictions 32. Is a prisoner in a correctional institution/facility 33. Actively involved in litigation or workman's compensation 34. Has participated in clinical studies evaluating investigational devices, pharmaceuticals or biologics within 6 months of randomization 35. Bedridden, confined to a wheelchair, or unable to walk 50 m without the help of a walker, crutches, or cane 36. Is currently taking prescription pain medication for any conditions other than ankle osteoarthritis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ankle osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Injury Care Research

    Boise, Idaho, 83713, United States

  • OrthoCarolina Foot and Ankle Institute

    Charlotte, North Carolina, 28207, United States

  • Orthopedic Specialists of Louisiana

    Shreveport, Louisiana, 71101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.